Clinical trials: Dose-Finding Study
Diarrhoea
A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants
The aim of the current clinical study was to evaluate, for the first time in humans (FTIH), the safety and immunogenicity of the altSonflex1-2-3 candidate vaccine against S. sonnei and S. flexneri serotypes 1b, 2a, and 3a.
- Trial name
- NCT05073003
- Testing
- AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose
- Where
- 2 sites in Belgium, Kenya
- Volunteers
- 551 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of…
- Trial name
- SONNET (NCT01199731)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine
- Where
- 41 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare
Open Angle Glaucoma, Ocular Hypertension
A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension
- Trial name
- NCT02129673
- Testing
- VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- ViSci Ltd.
Human Immunodeficiency Virus Type 1
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
- Trial name
- NCT00110305
- Testing
- TMC278 25 mg, TMC278 75 mg, TMC278 150 mg
- Where
- 40 sites in United States, Argentina and 12 more
- Volunteers
- 368 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Lateral Canthal Lines, Crow's Feet
Dose Finding Study In Subjects With Crow's Feet
The purpose of this study is to establish the therapeutic range of ANT-1401 in the treatment of Crow's Feet.
- Trial name
- NCT01951742
- Testing
- ANT-1401, Vehicle
- Where
- 10 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Anterios Inc.
Phenylketonuria
A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
The primary objective of the study is to evaluate the effect of dosing regimens of multiple subcutaneous (SC) doses of rAvPAL-PEG to induce an early and sustained Phe reduction while decreasing the frequency and severity of…
- Trial name
- NCT01560286
- Testing
- BMN 165 (rAvPAL-PEG)
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- BioMarin Pharmaceutical
Hyperthermic Intraperitoneal Chemotherapy
A Dose-finding Trial of Hyperthermic Intraperitoneal Docetaxel
This is a single-center study design, and 30 patients will be enrolled. Eligible patients will receive docetaxel at different dose levels according to the trial schedule.All the enrolled patients were treated with docetaxel…
- Trial name
- NCT05410483
- Testing
- Docetaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Obesity, Overweight
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing…
- Trial name
- NCT07752979
- Testing
- ABBV-295
- Where
- 64 sites in United States, Puerto Rico
- Volunteers
- 360 people
- Sponsor
- AbbVie
Carcinoid Syndrome
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.
- Trial name
- NCT01104415
- Testing
- Telotristat etiprate
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Lexicon Pharmaceuticals
Multiple Myeloma, NonHodgkin Lymphoma
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.
- Trial name
- NCT02978235
- Testing
- TAS4464
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Pancreatic Cancer
Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer
The main research objective is to work out the optimal doses of the novel combination of gemcitabine, oxaliplatin and imatinib mesylate (glivec) in patients with advanced pancreatic cancer that has progressed during or after…
- Trial name
- RPGOG1 (NCT01048320)
- Testing
- Gemcitabine, Oxaliplatin, Imatinib
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Diabetic Macular Edema
Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema
This study will evaluate the safety and efficacy of an intravitreal insert of fluocinolone acetonide for the treatment of diabetic macular edema.
- Trial name
- FAME (NCT00344968)
- Testing
- fluocinolone acetonide, Standard of care laser photocoagulation
- Where
- United States
- Volunteers
- 956 people
- Sponsor
- Alimera Sciences
Residual Neuromuscular Block (TOF-ratio of 0.2)
Sugammadex and Neostigmine at Residual Neuromuscular Blockade
This study is designed to compare recovery times after reversal of a residual neuromuscular block (TOF-ratio 0.2) with different doses of either neostigmine or sugammadex.
- Trial name
- SUNDRO20 (NCT01006720)
- Testing
- Sugammadex, Neostigmine, Saline
- Where
- Germany
- Volunteers
- 99 people
- Sponsor
- Technical University of Munich
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Trial name
- NCT02198482
- Testing
- Volasertib, Cytarabine, Daunorubicin
- Where
- 45 sites in Germany
- Volunteers
- 6 people
- Sponsor
- University of Ulm
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT02181218
- Testing
- Romidepsin, Gemcitabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
This phase I trial studies the side effects and best dose of a chemotherapy regimen given by continuous intravenous infusion (CI-CLAM), and to see how well it works in treating patients with acute myeloid leukemia that has come…
- Conditions
- Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04196010
- Testing
- Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
Dry Eye Disease (DED)
Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease
Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.
- Trial name
- NCT07656688
- Testing
- HUC1-394
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Huons Co., Ltd.
Pulmonary TB
Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB
This trial will assess the safety and efficacy of OPC-167832 combined with delamanid and bedaquiline in participants with drug-susceptible tuberculosis (DS-TB) administered for 17 weeks compared to rifampin, isoniazid…
- Trial name
- NCT05221502
- Testing
- Delamanid, Bedaquiline, RHEZ
- Where
- 6 sites in South Africa
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Local Analgesia Via Nerve Block
A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery
The objective of this study is to evaluate the efficacy, safety, and tolerability of bupivacaine liposomes for paravertebral nerve block in the treatment of thoracoscopic postoperative pain, and to evaluate the relevant human…
- Trial name
- NCT06529432
- Testing
- Bupivacaine Liposome Injection, Bupivacaine Hydrochloride Injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
CLL, Chronic Lymphocytic Leukemia
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
This is a trial in patients with previously untreated CLL. Eligible patients will receive Lenalidomide with a backbone of Fludarabine and Rituximab for 6 therapy cycles.
- Trial name
- NCT01703364
- Testing
- Lenalidomide
- Where
- 2 sites in Austria
- Volunteers
- 12 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie